Benzinga | Nov 29, 2021 06:07AM EST

Needham Initiates Coverage On Inozyme Pharma with Buy Rating, Announces Price Target of $23

Needham analyst Joseph Stringer initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Buy rating and announces Price Target of $23.